PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of frontneurologyLink to Publisher's site
 
Front Neurol. 2017; 8: 88.
Published online 2017 March 21. doi:  10.3389/fneur.2017.00088
PMCID: PMC5359221

Adenosine A2A Receptor Gene Knockout Prevents l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia by Downregulation of Striatal GAD67 in 6-OHDA-Lesioned Parkinson’s Mice

Abstract

l-3,4-Dihydroxyphenylalanine (l-DOPA) remains the primary pharmacological agent for the symptomatic treatment of Parkinson’s disease (PD). However, the development of l-DOPA-induced dyskinesia (LID) limits the long-term use of l-DOPA for PD patients. Some data have reported that adenosine A2A receptor (A2AR) antagonists prevented LID in animal model of PD. However, the mechanism in which adenosine A2AR blockade alleviates the symptoms of LID has not been fully clarified. Here, we determined to knock out (KO) the gene of A2AR and explored the possible underlying mechanisms implicated in development of LID in a mouse model of PD. A2AR gene KO mice were unilaterally injected into the striatum with 6-hydroxydopamine (6-OHDA) in order to damage dopamine neurons on one side of the brain. 6-OHDA-lesioned mice were then injected once daily for 21 days with l-DOPA. Abnormal involuntary movements (AIMs) were evaluated on days 3, 8, 13, and 18 after l-DOPA administration, and real-time polymerase chain reaction and immunohistochemistry for glutamic acid decarboxylase (GAD) 65 and GAD67 were performed. We found that A2AR gene KO was effective in reducing AIM scores and accompanied with decrease of striatal GAD67, rather than GAD65. These results demonstrated that the possible mechanism involved in alleviation of AIM symptoms by A2AR gene KO might be through reducing the expression of striatal GAD67.

Keywords: Parkinson’s disease, dyskinesia, adenosine A2A receptor, striatum, glutamic acid decarboxylase

Introduction

Parkinson’s disease (PD) is a common progressive neurodegenerative disorder characterized by bradykinesia, rigidity, resting tremor, and postural instability (1). The pathogenesis of PD has not been completely delineated, but believed to involve a multifactorial etiology including age-related, genetic, and environmental factors (2). Long-term therapy with l-3,4-dihydroxyphenylalanine (l-DOPA), the most common and effective symptomatic treatment for PD, often leads to the severe side effects such as dystonic, choreic, and ballistic movements, collectively referred to as l-DOPA-induced dyskinesia (LID) (3). Approximately 10% of patients have experienced LID in the first year of dopamine replacement therapy, and the incidence of LID is up to nearly 95% in patients who survive 15 years from diagnosis (4, 5). LID severely affects quality of life and leads to enormous social and economic burden to patients and their caregivers. Current effective treatment strategy for LID is mainly by a reduction in drug dose, which has a rebound of parkinsonian symptoms (6). Thus, an effective and satisfying management of LID is still urgently needed of PD therapy.

Basal ganglia is an important subcortical center for the regulation of voluntary movement, whose output pathways include the direct striatonigral–striatoentopeduncular gamma aminobutyric acid (GABA) pathway and the indirect striatopallidal GABA pathway (7). The unbalanced activities of basal ganglia output pathways were thought to be correlated with the development of the dyskinesias. Especially dysfunction of the indirect pathway can indirectly cause alterations in the pallidothalamic output (8). Adenosine A2A receptor (A2AR), which acts in opposition to dopamine D2 receptor (D2R) and colocalized with D2R in indirect striatopallidal GABAergic pathway, offers a unique opportunity to modulate basal ganglia function mediated by dopamine (9). Pharmacological antagonists of A2AR prevented dopamine-induced motor complications and significantly increased l-DOPA efficacy in rats and primates when administered with l-DOPA (10, 11). On the basis of recent preclinical studies performed using A2AR antagonists as well as the good curative effect obtained, A2AR antagonists appear to be a promising non-dopaminergic therapy for PD (1214). Unfortunately, the mechanism by which adenosine A2AR blockade alleviates the symptoms of LID has not been fully clarified.

As the neurotransmitter of striatal projection neurons, GABA might play a role in LID (15). Studies have shown that the chronic systemic administration of l-DOPA to 6-OHDA-lesioned rats increased GABA release in the substantia nigra (16, 17) and GABA-synthesizing enzyme glutamic acid decarboxylase (GAD) gene expression in striatonigral neurons (1820). GAD, the rate-limiting enzyme responsible for the production of GABA, is classified into two major types: GAD65 and GAD67. GAD65 and GAD67 are derived from two different genes, which are located on chromosome 10 and chromosome 2, respectively (21). The reason why GAD67 and GAD65 are so named is that their apparent molecular weights are 65,400 and 66,600 Da, respectively. GAD65 is largely present as an inactive apoenzyme (GAD without bound cofactor; apoGAD), thus providing a reservoir of inactive GAD that can be drawn on when additional GABA synthesis is required, while GAD67 is by and large present as a permanently active pyridoxal phosphate-bound holoenzyme (2224). A regional difference exists in the relative expression of these two isoforms of GAD. Comparative in situ hybridization in rat brain showed high relative levels of GAD67 mRNA were expressed in brain regions such as medial septal nucleus, neocortex, inferior colliculus, and cerebellum, while GAD65 mRNA was particularly abundant in regions such as olfactory tubercle, zona incerta, and substantia nigra (25). In the matter of subcellular distributions, GAD65 was preferentially found in nerve terminals, while GAD67 was located more equally in the cytoplasm as well as in nerve terminals, which suggested that GAD67 might be involved in the synthesis of GABA for general metabolic activity, whereas GAD65 was involved in synaptic transmission (26). Several lines of evidence have revealed that LID in experimental models of PD was associated with an overexpression of GAD mRNA on striatal output neurons (19, 20, 2729). Between these two neurotransmitter-related mRNAs, GAD67 mRNA has mainly been the focus of the study and considered to be positively correlated with the dyskinesia. The upregulation of GAD67 mRNA following the dopamine-denervated lesion was paralleled by increased GAD enzyme activity and extracellular levels of GABA in the striatum (28, 30). In addition, the antagonistic adenosine A2A and D2R interaction occurring in striatopallidal GABAergic pathways also regulates GABAergic neurotransmission in these areas (31). When adenosine levels rise in the basal ganglia, the activation of A2AR abolished dopamine D2 agonist-induced inhibition of GABA release (7, 3234). Whereas A2AR antagonists could potentiate this inhibitory effect and reduced the release of GABA (31).

Based on these findings, it can be hypothesized that there is an association between adenosine A2AR and GAD. Thus, the aim of our study is to explore the effect of adenosine A2AR knockout (KO) on the expression of GAD67 and GAD65 in striatal neurons in LID.

Animals and Methods

Animals

The A2AR KO mice were purchased from the Jackson Laboratory and were established on the Balb/c strain background. Wild-type (WT) Balb/c mice were purchased from Slac Laboratory Animal Company. KO mice were crossed with WT mice to get the heterozygous mice, and then, the heterozygous mice were crossed with each other to get the KO mice and WT mice. A2AR homozygous KO mice and WT Balb/c mice were bred at the Laboratory Animal Centre of Wenzhou Medical University. Experiments were conducted on 24 WT and 24 adenosine A2AR gene KO adult male mice weighing 25–30 g on arrival, which was further randomly assigned to the following three experimental groups (eight per group): the sham group, the PD group, and the LID group. All of the mice were housed under a 12-h light:12-h dark cycle, temperature 22.0 ± 2.0°C, and relative humidity of 55 ± 10%. Food and water were available ad libitum. All procedures associated with the care of animals were performed according to the National Institutes of Health for the care and use of laboratory animals (NIH publication No 80-23) and were approved by the Animal Ethics Committee of Wenzhou Medical University. All efforts were made to reduce the number of animals used.

Induction of Parkinsonism and LID

Unilateral 6-OHDA lesions were performed according to the previous standard procedure (35, 36). Briefly, mice were anesthetized with chloral hydrate (0.3 g/kg, i.p.) and placed in the stereotaxic frame. Two microliters of 6-OHDA (1 mg 6-OHDA dissolved in 200 μl 0.05% ascorbic acid) were stereotaxically injected into the left striatum (relative to bregma and dura): anterior–posterior: −0.5 mm, medial–lateral: +2.0 mm, and dorsoventral: −2.8 mm with a Hamilton syringe at a speed of 0.4 μl/min. The sham-operated mice were similarly treated but received physiological saline containing 0.2% ascorbic acid instead of 6-OHDA. After injections, mice were kept warm (37°C) until they recovered from surgery. Three weeks later, the lesioned mice were evaluated by rotation test over 30 min after apomorphine (0.5 mg/kg, i.p.) administration, and only severely lesioned animals were selected for the next experiment (more than 7 full-body turns/min toward the side of the unlesioned side). One day after apomorphine test, they were then treated with 25 mg/kg l-DOPA and 6.25 mg/kg benserazide (i.p. injection/day) for 3 weeks in order to induce a mouse model of dyskinesia.

Abnormal Involuntary Movement (AIM) Ratings

Abnormal involuntary movements were evaluated on days 3, 8, 13, and 18 after l-DOPA administration. After the daily injection of l-DOPA, the mice were observed individually for 1 min every 20 min from 20 to 120 min. At each observation time point, the AIMs were classified into three subtypes: axial, limb, and orolingual movements as detailed by Lindenbach et al. (37). Each subtype was scored on a severity scale from 0 to 4 (0 = absent, 1 = present during less than half of the observation time, 2 = present for more than half of the observation time, 3 = present for 1 min but suppressible by external stimuli, and 4 = present all the time but not suppressible by external stimuli). For each mouse, the total AIM score for each test session was calculated by summing the three individual dyskinesia scores.

Real-time Polymerase Chain Reaction

The expression levels of GAD65 and GAD67 were measured using real-time polymerase chain reaction. Total RNA was extracted from the brain striatum of lesioned hemisphere using TriZol (Ambion, USA) and reverse transcribed into cDNA using the PrimeScript RT Reagent Kit (Takara, Japan). Quantitative polymerase chain reaction was performed in a 25-μl reaction mixture using SYBR Premix Ex Taq™ II (Takara, Japan) according to the manufacturer’s instructions. The amplification of the housekeeping gene β-GAPDH cDNA was used as an internal control. Forward and reverse primers, respectively, used for PCR were 5′-CACCTGCGACCAAAAACCC-3′ and 5′-AGATGACCATGCGGAAGAAG-3′ for GAD65, and 5′-CTCCCTTCTTCAGGCTCTCCC-3′ and 5′-GGTCTTGGGGTCTCTACGGTTC-3′ for GAD67.

Histological and Immunohistochemical Analyses

In terms of histological and immunohistochemical analysis, we extract the whole striatum section (both dorsal and ventral) to stain. Experimental mice were anesthetized with 10% chloral hydrate (0.3 g/kg, i.p.), and perfused transcardially with saline and then fixed by perfusion with 4% paraformaldehyde. Brains were removed and prepared as 4-μm paraffin-embedded sections. Endogenous peroxidase was blocked with 3% H2O2, and tissue was treated overnight at 4°C with primary antibodies:mouse monoclonal antibody against GAD67 (1:1,000 dilution, Millipore), or rabbit polyclonal antibody against GAD65 (1:1,000 dilution, Sigma). Sections were then incubated with the secondary antibody for 1 h at room temperature, followed by coloration with 3,3-diaminobenzidine (DAB, Sigma, Germany) and hematoxylin counterstaining. The sections were washed with 0.01 mol/l PBS between each step. We analyzed the average integral optical density (IOD) of cells positively stained with GAD65 or GAD67 and calculated the mean values and SDs. Three regions of interest were randomly chosen from each section for quantification by using Image-Pro Plus 6.0.

Statistical Analysis

Measurement data were expressed as mean ± SD. Significance of the difference between two groups was analyzed using two-tailed Student’s t-test. Multiple groups were compared using one-way analysis of variance (ANOVA) and followed by LSD post hoc comparisons when appropriate. All statistical analyses were performed with SPSS 20.0 software (IBM, Armonk, NY, USA) and GraphPad Prism 6.05 (GraphPad, La Jolla, CA, USA). P < 0.05 was considered statistically significant.

Results

Effects of Adenosine A2AR Gene KO on the Behavior of Mice with LID

In this study, in the process of induction of 6-OHDA-lesioned PD mice, the survival rate and the rate of successful lesions are about 80 and 50%, respectively. PD rats treated with l-DOPA for 18 days developed a progressive increase in LID as indicated by AIM score. Median AIM score of WT-LID increased from 59.63 ± 8.12 on day 3 to 79.88 ± 5.46 on day 18 (n = 8, Ftime = 12.32, P < 0.05 compared with day 3, ANOVA and followed by LSD post hoc analysis, Figure Figure1).1). After KO of adenosine A2AR gene, similar trend of AIM score was found, namely, increased from 44.75 ± 7.61 on day 3 to 64.00 ± 7.80 on day 13, and 60.5 ± 6.5 on day 18 (n = 8, Ftime = 0.523, P > 0.05 compared with day 13, ANOVA and followed by LSD post hoc analysis, Figure Figure1).1). It is remarkable that AIM score of A2A−/− LID group was obviously lower compared to the WT-LID group at the same time point (n = 8, P < 0.05, two-tailed Student’s t-test, Figure Figure11).

Figure 1
Time course of abnormal involuntary movement (AIM) scores development with l-3,4-dihydroxyphenylalanine (l-DOPA) plus benserazide exposure. AIM scores in wild-type (WT)-l-3,4-dihydroxyphenylalanine-induced dyskinesia (LID) group, A2A−/− ...

Effects of Adenosine A2AR Gene KO on GAD65 and GAD67 Expression in the Striatum of Mice with LID

Immunohistochemistry

Immunohistochemical studies showed significant increase of GAD65 (sham: 0.063 ± 0.007; PD: 0.081 ± 0.007; LID: 0.168 ± 0.013) and GAD67 (sham: 0.012 ± 0.001; PD: 0.055 ± 0.006; LID: 0.109 ± 0.010) in WT-LID compared to WT-sham and WT-PD groups (n = 4, P < 0.05, two-tailed Student’s t-test, Figure Figure2).2). In A2AR gene KO groups, treatment with l-DOPA (LID group) can significantly increase the IOD of both GAD65 (sham: 0.056 ± 0.004; PD: 0.092 ± 0.015; LID: 0.149 ± 0.013) and GAD67 (sham: 0.014 ± 0.005; PD: 0.036 ± 0.007; LID: 0.072 ± 0.013) (n = 4, Ftreatment = 5.324, P < 0.05 vs. PD group or sham group, ANOVA and followed by LSD post hoc analysis, Figure Figure2).2). When comparing the IOD of GAD67, WT-LID group was significantly higher than A2A−/− LID group (n = 4, P < 0.01, two-tailed Student’s t-test, Figure Figure2).2). However, there was no significant difference of GAD65 between WT-LID and A2A−/− LID groups (n = 4, P > 0.05, two-tailed Student’s t-test, Figure Figure22).

Figure 2
Effects of adenosine A2A receptor (A2AR) gene knockout (KO) on striatal GAD65 and GAD67 expression. (A) Representative images of GAD65 immunohistochemistry studies in sham, 6-OHDA-lesioned wild-type (WT), or A2AR gene KO mice treated with vehicle or pulsatile ...

Real-time Polymerase Chain Reaction

Real-time polymerase chain reaction showed significant increase of GAD65 (sham: 0.93 ± 0.05; PD: 1.58 ± 0.15; LID: 2.12 ± 0.18) and GAD67 (sham: 0.98 ± 0.03; PD: 1.35 ± 0.10; LID: 2.03 ± 0.26) mRNA expression in WT-LID compared to WT-sham and WT-PD groups (n = 4, P < 0.05, two-tailed Student’s t-test, Figure Figure3).3). In A2AR gene KO groups, treatment with l-DOPA (LID group) can significantly increase the mRNA expression of both GAD65 (sham: 1.05 ± 0.07; PD: 1.25 ± 0.11; LID: 1.55 ± 0.57) and GAD67 (sham: 0.85 ± 0.05; PD: 1.12 ± 0.12; LID: 1.63 ± 0.10) (n = 4, Ftreatment = 11.23, P < 0.05 vs. PD group or sham group, ANOVA and followed by LSD post hoc analysis, Figure Figure2).2). In 6-OHDA lesioned mice treated with l-DOPA, striatal GAD67 mRNA level was significant lower in the A2A−/− LID group compared to WT-LID group (n = 4, P < 0.01, two-tailed Student’s t-test, Figure Figure3).3). However, when comparing the mRNA expression of GAD65, the WT-PD group shows a milder increase compared to A2A−/− PD group and a decrease in A2A−/− LID group in contrast to WT-LID. Nevertheless, there was no significant difference between two groups (n = 4, P > 0.05, two-tailed Student’s t-test, Figure Figure33).

Figure 3
Effects of adenosine A2A receptor gene knockout on striatal GAD65 and GAD67 mRNA expression. (A) There was no significant difference of striatal GAD65 mRNA expression between wild-type (WT)-l-3,4-dihydroxyphenylalanine-induced dyskinesia (LID) and A2A ...

Discussion

The present study showed that A2AR gene KO reduced the severity of LID induced by subchronic l-DOPA in 6-OHDA-lesioned mice. A2AR gene KO also reversed the effects of l-DOPA on GAD67, but not GAD65 expression in striatal projection neurons. These data supported the hypothesis that deletion of A2AR gene alleviated LID via downregulating the expression of striatal GAD67.

l-3,4-Dihydroxyphenylalanine remains the primary pharmacological agent for the symptomatic treatment of PD. However, the development of LID limits the long-term use of l-DOPA for PD patients. Recent studies showed that A2AR might play an important role in the treatment of LID. Thus, in the present study, we determined to KO the gene of A2AR and explored the possible underlying mechanisms implicated in development of LID in a mouse model of PD.

Previous experimental data have showed that chronic l-DOPA treatment significantly increased the level of striatal A2AR mRNA in normal monkeys exhibiting marked dyskinesia (38). Consistent with this, two recent positron emission tomography studies have reported that there were higher levels of A2AR binding in dyskinetic PD patients compared with non-dyskinesia (39, 40). Some data have reported that A2AR antagonists prevented dopamine-induced motor complications in 6-OHDA-lesioned rodent animal model of PD (41) and MPTP-treated primates (42). These findings provided overwhelming evidence for the assumption that blockade of A2ARs on striatopallidal neurons of the indirect pathway may have a beneficial antidyskinetic potentiality (43).

As previous A2AR antagonists have been certified for their properties of inability to worsen established dyskinesia, we found that A2AR gene KO was effective in reducing AIM scores. The peak of AIM scores appeared beforehand at day 12 in A2A−/− LID group, while WT-LID group was still in the process of developing LID. And severity of dyskinesia was significantly alleviated by A2AR KO during the whole observation period. These findings again provided directly strong evidence for the beneficial antidyskinetic potentiality of A2AR deficiency against the development of LID, which well verified the above assumption.

As described above, the A2AR gene-deficient mice induced to dyskinesia by administration of l-DOPA (25 mg/kg) presented a relatively low AIM score in our study. However, the mechanism of the alleviation of dyskinesia symptoms by A2AR KO is unclear. Possible pathway might include D2R, since A2AR is largely co-expressed with D2R and antagonizes D2R-mediated behavioral and neurochemical effects in the basal ganglia through a form of antagonistic A2A–D2 heteromeric receptor complexes in the striatum where it modulates dopaminergic neurons activity (44). Moreover, enhanced GABA release was found in dyskinetic rats (16), and studies have showed that A2AR could affect the release of GABA via D2R. For instance, blockade of striatal A2AR reduced the dopamine D2R-mediated GABA release, whereas activation of A2AR promoted the release of GABA (45). However, what should also be noted is that the regulation of striatopallidal neurons mediated by A2AR does not completely ascribe to antagonistic A2AR–D2R heterodimer since the stimulatory effect of adenosine A2AR antagonists on motor activity is still present in D2 KO mice (46, 47). Hence, endogenous adenosine via A2AR at least partly regulates the activity of striatopallidal transmission in a dopamine D2R-independent manner and that other mechanisms that can also affect GABA release in the striatum might be of importance upon dopamine depletion (13, 48).

Glutamic acid decarboxylase, as the rate-limiting enzyme responsible for the production of GABA, was reasonably taken into our consideration. Our finding that unilateral degeneration of nigrostriatal dopaminergic neurons increased striatal GAD65 and GAD67 gene expression was consistent with a previous study (49), which has been thought involved in the activation of the indirect striatopallidal GABA pathway (50). GABA neurons in the striatum appear as medium-sized spiny projection neurons, medium-sized aspiny interneurons, and large-sized aspiny interneurons, all of which have synaptic connections from dopaminergic nerve terminals. GAD-immunoreactive GABA neurons in the striatum constitute most of the medium-sized spiny neurons with efferent projections (5153). Dopamine, as is well known, can inhibit downstream GABA release in the globus pallidus by binding to Gi-coupled D2Rs located in the striatum. The dopamine-denervated lesion increased extracellular levels of GABA and simultaneously upregulated GAD65 and GAD67 gene expression in the striatum. The increase in GAD67 gene expression is restricted to a small population (approximately 10% of all striatal GABA neurons) of medium-sized projection neurons (18, 54). Chronic intermittent administration of l-DOPA (20 mg/kg) to mice with 6-OHDA lesion induced dyskinesia, thereby leading to further increases in GAD65 and GAD67 gene expression. The progressive increase in GAD gene expression was paralleled by an increase in GABA synthesis in striatopallidal neurons (20). Thus, the massive increase of GAD induced by chronic intermittent l-DOPA (20 mg/kg) administration in the damaged striatum appeared to be related to dopamine neuron degeneration.

As found in the present study, A2A−/− LID group was accompanied with a significant decrease in GAD67, which is involved in general metabolic processes activity and is considered an index of GABA neuron activity (55). However, it did not produce significant modifications in striatal GAD65. The effects of A2AR KO were more pronounced on GAD67 than on GAD65, suggesting that GAD65 might not play a similar role as GAD67 on the sensitized behavioral responses to l-DOPA (20). It seems that different mechanisms might be involved in the regulation of these two GAD genes in striatopallidal neurons (49). GABA is synthesized by two distinct enzymes GAD67 and GAD65 that differ in their cellular localization, functional properties, and cofactor requirements. GAD67 exists as both homo- and heterodimers in both soluble and membrane-bound forms, primarily within the cell soma but also to a limited degree in terminals (56). During the development, GAD67, but not GAD65, deleted homozygous mice die immediately after birth and had only less than 10% of normal brain GABA levels (57). In the adult, it is critical for maintaining intracellular GABA reserves for metabolic activity and other functions such as synaptogenesis and protection against neuronal injury, rather than for vesicular release. GAD67 protein contents can be influenced by the level of intraneuronal GABA, and this occurrence was not associated with a change in GAD67 mRNA levels (58, 59). Also, there appears to be isoform-specific physiological feedback, in that GAD67 mRNA and protein levels, rather than GAD65, were increased in cortical neurons after sensory learning (60, 61). This is the reason, at least in part, GAD67 contributed to alleviating LID of A2AR KO mice.

In summary, the present study indicated that A2AR KO had an important effect on the expression of striatal GAD67, which might affect the production of GABA and thus further alleviate dyskinesia.

Author Contributions

G-qZ conceived and designed the experiment. S-bY, X-gZ, SC, W-tY, and X-wZ performed the experiments. S-bY analyzed and interpreted the data. X-gZ, S-bY, and G-qZ wrote the article. All the authors read and approved the final manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

This project was supported by the grant of the Administration of Traditional Chinese Medicine of Zhejiang Province (2010ZQ010); Wenzhou Municipal Science and Technology Bureau in Zhejiang province (Y20130337); Young and Middle-Aged University Discipline Leaders of Zhejiang Province, China (2013277); and Zhejiang Provincial Program for the Cultivation of High-level Health talents (2015).

References

1. Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med (2013) 368:610–22.10.1056/NEJMoa1205158 [PubMed] [Cross Ref]
2. Tolleson CM, Fang JY.. Advances in the mechanisms of Parkinson’s disease. Discov Med (2013) 15:61–6.10.1016/bs.ctdb.2016.07.005 [PubMed] [Cross Ref]
3. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM.. The pharmacology of l-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol Rev (2013) 65:171–222.10.1124/pr.111.005678 [PubMed] [Cross Ref]
4. Hely MA, Morris JG, Reid WG, Trafficante R.. Sydney Multicenter Study of Parkinson’s disease: non-l-DOPA-responsive problems dominate at 15 years. Mov Disord (2005) 20:190–9.10.1002/mds.20324 [PubMed] [Cross Ref]
5. Bhidayasiri R, Truong DD.. Motor complications in Parkinson disease: clinical manifestations and management. J Neurol Sci (2008) 266:204–15.10.1016/j.jns.2007.08.028 [PubMed] [Cross Ref]
6. Iravani MM, Jenner P.. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm (Vienna) (2011) 118:1661–90.10.1007/s00702-011-0698-2 [PubMed] [Cross Ref]
7. Fuxe K, Ferre S, Genedani S, Franco R, Agnati LF.. Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol Behav (2007) 92:210–7.10.1016/j.physbeh.2007.05.034 [PubMed] [Cross Ref]
8. Kanda T, Uchida S.. Clinical/pharmacological aspect of adenosine A2A receptor antagonist for dyskinesia. Int Rev Neurobiol (2014) 119:127–50.10.1016/b978-0-12-801022-8.00006-4 [PubMed] [Cross Ref]
9. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K.. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci (1997) 20:482–7.10.1016/S0166-2236(97)01096-5 [PubMed] [Cross Ref]
10. Bibbiani F, Oh JD, Petzer JP, Castagnoli N, Jr, Chen JF, Schwarzschild MA, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease. Exp Neurol (2003) 184:285–94.10.1016/S0014-4886(03)00250-4 [PubMed] [Cross Ref]
11. Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA.. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Prog Neurobiol (2007) 83:293–309.10.1016/j.pneurobio.2007.07.001 [PubMed] [Cross Ref]
12. Feigin A. Nondopaminergic symptomatic therapies for Parkinson’s disease: turn on or turn off? Neurology (2003) 61:286–7.10.1212/WNL.61.3.286 [PubMed] [Cross Ref]
13. Pinna A, Wardas J, Simola N, Morelli M.. New therapies for the treatment of Parkinson’s disease: adenosine A2A receptor antagonists. Life Sci (2005) 77:3259–67.10.1016/j.lfs.2005.04.029 [PubMed] [Cross Ref]
14. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M.. Targeting adenosine A2A receptors in Parkinson’s disease. Trends Neurosci (2006) 29:647–54.10.1016/j.tins.2006.09.004 [PubMed] [Cross Ref]
15. Zhang K, Chammas C, Soghomonian JJ.. Loss of glutamic acid decarboxylase (GAD67) in striatal neurons expressing the Drdr1a dopamine receptor prevents l-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice. Neuroscience (2015) 303:586–94.10.1016/j.neuroscience.2015.07.032 [PubMed] [Cross Ref]
16. Yamamoto N, Pierce RC, Soghomonian JJ.. Subchronic administration of l-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata. Brain Res (2006) 1123:196–200.10.1016/j.brainres.2006.09.027 [PubMed] [Cross Ref]
17. Mela F, Marti M, Bido S, Cenci MA, Morari M.. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiol Dis (2012) 45:573–82.10.1016/j.nbd.2011.09.015 [PubMed] [Cross Ref]
18. Soghomonian JJ, Gonzales C, Chesselet MF.. Messenger RNAs encoding glutamate-decarboxylases are differentially affected by nigrostriatal lesions in subpopulations of striatal neurons. Brain Res (1992) 576:68–79.10.1016/0006-8993(92)90610-L [PubMed] [Cross Ref]
19. Carta AR, Fenu S, Pala P, Tronci E, Morelli M.. Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats. Eur J Neurosci (2003) 18:2563–72.10.1046/j.1460-9568.2003.02983.x [PubMed] [Cross Ref]
20. Katz J, Nielsen KM, Soghomonian JJ.. Comparative effects of acute or chronic administration of levodopa to 6-hydroxydopamine-lesioned rats on the expression of glutamic acid decarboxylase in the neostriatum and GABAA receptors subunits in the substantia nigra, pars reticulata. Neuroscience (2005) 132:833–42.10.1016/j.neuroscience.2004.12.032 [PubMed] [Cross Ref]
21. Bu DF, Erlander MG, Hitz BC, Tillakaratne NJ, Kaufman DL, Wagner-McPherson CB, et al. Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene. Proc Natl Acad Sci U S A (1992) 89:2115–9.10.1073/pnas.89.6.2115 [PubMed] [Cross Ref]
22. Miller LP, Walters JR, Martin DL. Post-mortem changes implicate adenine nucleotides and pyridoxal-5’-phosphate in regulation of brain glutamate decarboxylase. Nature (1977) 266:847–8.10.1038/266847a0 [PubMed] [Cross Ref]
23. Kaufman DL, Houser CR, Tobin AJ.. Two forms of the gamma-aminobutyric acid synthetic enzyme glutamate decarboxylase have distinct intraneuronal distributions and cofactor interactions. J Neurochem (1991) 56:720–3.10.1111/j.1471-4159.1991.tb08211.x [PubMed] [Cross Ref]
24. Martin DL, Martin SB, Wu SJ, Espina N.. Regulatory properties of brain glutamate decarboxylase (GAD): the apoenzyme of GAD is present principally as the smaller of two molecular forms of GAD in brain. J Neurosci (1991) 11:2725–31. [PubMed]
25. Erlander MG, Tillakaratne NJ, Feldblum S, Patel N, Tobin AJ.. Two genes encode distinct glutamate decarboxylases. Neuron (1991) 7:91–100.10.1016/0896-6273(91)90077-D [PubMed] [Cross Ref]
26. Erlander MG, Tobin AJ.. The structural and functional heterogeneity of glutamic acid decarboxylase: a review. Neurochem Res (1991) 16:215–26.10.1007/BF00966084 [PubMed] [Cross Ref]
27. Soghomonian JJ, Pedneault S, Blanchet PJ, Goulet M, Di Paolo T, Bedard PJ.. l-DOPA regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys. Brain Res Mol Brain Res (1996) 39:237–40.10.1016/0169-328X(96)00078-2 [PubMed] [Cross Ref]
28. Cenci MA, Lee CS, Bjorklund A.. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci (1998) 10:2694–706.10.1046/j.1460-9568.1998.00285.x [PubMed] [Cross Ref]
29. Nielsen KM, Soghomonian JJ.. Normalization of glutamate decarboxylase gene expression in the entopeduncular nucleus of rats with a unilateral 6-hydroxydopamine lesion correlates with increased GABAergic input following intermittent but not continuous levodopa. Neuroscience (2004) 123:31–42.10.1016/j.neuroscience.2003.08.010 [PubMed] [Cross Ref]
30. Lindefors N.. Dopaminergic regulation of glutamic acid decarboxylase mRNA expression and GABA release in the striatum: a review. Prog Neuropsychopharmacol Biol Psychiatry (1993) 17:887–903.10.1016/0278-5846(93)90018-N [PubMed] [Cross Ref]
31. Khisti RT, Chopde CT, Abraham E.. GABAergic involvement in motor effects of an adenosine A(2A) receptor agonist in mice. Neuropharmacology (2000) 39:1004–15.10.1016/S0028-3908(99)00187-2 [PubMed] [Cross Ref]
32. Mayfield RD, Suzuki F, Zahniser NR.. Adenosine A2A receptor modulation of electrically evoked endogenous GABA release from slices of rat globus pallidus. J Neurochem (1993) 60:2334–7.10.1111/j.1471-4159.1993.tb03526.x [PubMed] [Cross Ref]
33. Dayne Mayfield R, Larson G, Orona RA, Zahniser NR.. Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2a/D2 receptor interaction in globus pallidus. Synapse (1996) 22:132–8.10.1002/(SICI)1098-2396(199602)22:2<132::AID-SYN6>3.0.CO;2-E [PubMed] [Cross Ref]
34. Shindou T, Richardson PJ, Mori A, Kase H, Ichimura M.. Adenosine modulates the striatal GABAergic inputs to the globus pallidus via adenosine A2A receptors in rats. Neurosci Lett (2003) 352:167–70.10.1016/j.neulet.2003.08.059 [PubMed] [Cross Ref]
35. Virgone-Carlotta A, Uhlrich J, Akram MN, Ressnikoff D, Chretien F, Domenget C, et al. Mapping and kinetics of microglia/neuron cell-to-cell contacts in the 6-OHDA murine model of Parkinson’s disease. Glia (2013) 61:1645–58.10.1002/glia.22546 [PubMed] [Cross Ref]
36. Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. UK: Academic Press; (2001).
37. Lindenbach D, Ostock CY, Eskow Jaunarajs KL, Dupre KB, Barnum CJ, Bhide N, et al. Behavioral and cellular modulation of l-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat. J Pharmacol Exp Ther (2011) 337:755–65.10.1124/jpet.111.179416 [PubMed] [Cross Ref]
38. Zeng BY, Pearce RK, MacKenzie GM, Jenner P. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l-DOPA. Eur J Neurosci (2000) 12:1096–104.10.1046/j.1460-9568.2000.00988.x [PubMed] [Cross Ref]
39. Mishina M, Ishiwata K, Naganawa M, Kimura Y, Kitamura S, Suzuki M, et al. Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson’s disease patients. PLoS One (2011) 6:e17338.10.1371/journal.pone.0017338 [PMC free article] [PubMed] [Cross Ref]
40. Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ.. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology (2011) 76:1811–6.10.1212/WNL.0b013e31821ccce4 [PMC free article] [PubMed] [Cross Ref]
41. Hickey P, Stacy M.. Adenosine A2A antagonists in Parkinson’s disease: what’s next? Curr Neurol Neurosci Rep (2012) 12:376–85.10.1007/s11910-012-0279-2 [PubMed] [Cross Ref]
42. Hodgson RA, Bedard PJ, Varty GB, Kazdoba TM, Di Paolo T, Grzelak ME, et al. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Exp Neurol (2010) 225:384–90.10.1016/j.expneurol.2010.07.011 [PubMed] [Cross Ref]
43. Tomiyama M.. Adenosine receptors and dyskinesia in pathophysiology. Int Rev Neurobiol (2014) 119:117–26.10.1016/b978-0-12-801022-8.00005-2 [PubMed] [Cross Ref]
44. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, et al. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci U S A (2001) 98:1970–5.10.1073/pnas.98.4.1970 [PubMed] [Cross Ref]
45. Ferre S, O’Connor WT, Fuxe K, Ungerstedt U.. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci (1993) 13:5402–6. [PubMed]
46. Aoyama S, Kase H, Borrelli E.. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci (2000) 20:5848–52. [PubMed]
47. Zahniser NR, Simosky JK, Mayfield RD, Negri CA, Hanania T, Larson GA, et al. Functional uncoupling of adenosine A(2A) receptors and reduced response to caffeine in mice lacking dopamine D2 receptors. J Neurosci (2000) 20:5949–57. [PubMed]
48. Kirk IP, Richardson PJ.. Adenosine A2A receptor-mediated modulation of striatal [3H]GABA and [3H]acetylcholine release. J Neurochem (1994) 62:960–6.10.1046/j.1471-4159.1994.62030960.x [PubMed] [Cross Ref]
49. Yamamoto N, Soghomonian JJ.. Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience (2009) 163:1171–80.10.1016/j.neuroscience.2009.07.060 [PMC free article] [PubMed] [Cross Ref]
50. Carta AR, Pinna A, Cauli O, Morelli M.. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent l-DOPA and A2A receptor blockade plus l-DOPA in dopamine-denervated rats. Synapse (2002) 44:166–74.10.1002/syn.10066 [PubMed] [Cross Ref]
51. Fisher RS, Buchwald NA, Hull CD, Levine MS.. The GABAergic striatonigral neurons of the cat: demonstration by double peroxidase labeling. Brain Res (1986) 398:148–56.10.1016/0006-8993(86)91260-6 [PubMed] [Cross Ref]
52. Kita H, Kitai ST.. Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations. Brain Res (1988) 447:346–52.10.1016/0006-8993(88)91138-9 [PubMed] [Cross Ref]
53. Mugnaini E, Oertel WH. Handbook of neuroanatomy: GABA and neuropeptides in the CNS, part 1–4. In: Bjorklund A, Hiikfelt T, editors. , editors. An Atlas of the Distribution of GABAergic Neurons and Terminals in the Rat CNS as Revealed by GAD Immunohistochemistry. Amsterdam: Elsevier; (1985). p. 436–608.
54. Lindefors N, Brene S, Herrera-Marschitz M, Persson H.. Region specific regulation of glutamic acid decarboxylase mRNA expression by dopamine neurons in rat brain. Exp Brain Res (1989) 77:611–20.10.1007/BF00249614 [PubMed] [Cross Ref]
55. Soghomonian JJ, Martin DL.. Two isoforms of glutamate decarboxylase: why? Trends Pharmacol Sci (1998) 19:500–5.10.1016/S0165-6147(98)01270-X [PubMed] [Cross Ref]
56. Kanaani J, Lissin D, Kash SF, Baekkeskov S.. The hydrophilic isoform of glutamate decarboxylase, GAD67, is targeted to membranes and nerve terminals independent of dimerization with the hydrophobic membrane-anchored isoform, GAD65. J Biol Chem (1999) 274:37200–9.10.1074/jbc.274.52.37200 [PubMed] [Cross Ref]
57. Asada H, Kawamura Y, Maruyama K, Kume H, Ding RG, Kanbara N, et al. Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci U S A (1997) 94:6496–9.10.1073/pnas.94.12.6496 [PubMed] [Cross Ref]
58. Rimvall K, Sheikh SN, Martin DL.. Effects of increased gamma-aminobutyric acid levels on GAD67 protein and mRNA levels in rat cerebral cortex. J Neurochem (1993) 60:714–20.10.1111/j.1471-4159.1993.tb03206.x [PubMed] [Cross Ref]
59. Rimvall K, Martin DL.. The level of GAD67 protein is highly sensitive to small increases in intraneuronal gamma-aminobutyric acid levels. J Neurochem (1994) 62:1375–81.10.1046/j.1471-4159.1994.62041375.x [PubMed] [Cross Ref]
60. Gierdalski M, Jablonska B, Siucinska E, Lech M, Skibinska A, Kossut M.. Rapid regulation of GAD67 mRNA and protein level in cortical neurons after sensory learning. Cereb Cortex (2001) 11:806–15.10.1093/cercor/11.9.806 [PubMed] [Cross Ref]
61. Lech M, Skibinska A, Siucinska E, Kossut M.. Learning-induced plasticity of cortical representations does not affect GAD65 mRNA expression and immunolabeling of cortical neuropil. Brain Res (2005) 1044:266–71.10.1016/j.brainres.2005.02.077 [PubMed] [Cross Ref]

Articles from Frontiers in Neurology are provided here courtesy of Frontiers Media SA